NNZ-2591 Receives Orphan Drug Designation For Treatment Of Prader-Willi

Release Date: 27-Sep-2021

US FDA granted the orphan designation to NNZ-2591 for treating Prader-Willi, a neurodevelopmental disorder. Neuren Pharmaceuticals outcome of the trial using a mouse model of Prader-Willi syndrome, which saw treatment for six weeks normalize fat mass, insulin levels and all behavioral deficits has shown a positive result.


In Infants this disease causes low muscle tone and faces difficulty in feeding and later develops a range of intellectual and learning disabilities, growth hormone deficiency, sleep disturbances and speech difficulties, along with constant hunger and difficulty controlling emotions.

Need custom market research solution? We can help you with that too.